Covid19_manual_annotation  

2020PubMed@AikoHIRAKI:re32807241 JSONTXT

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue ForCovid19 correct/standard/original word details tao:has_database_id typo
T142 0-12 TrialDesign denotes Multi-centre
T143 14-23 TrialDesign denotes three arm
T144 25-46 TrialDesign denotes randomized controlled
T223 60-63 TrialDesign denotes use
6 67-85 Chemical denotes methylprednisolone drug MESH:D008775
7 90-112 Chemical denotes unfractionated heparin drug MESH:D006493
T64 116-130 Severity denotes critically ill
T145 131-141 Status_of_Care denotes ventilated
9 142-150 Species denotes patients Tax:9606
10 156-165 Disease denotes pneumonia MESH:D011014
11 171-181 Disease denotes SARS-CoV-2 MESH:D000086382
T147 182-191 Disease denotes infection MESH:MESH:D007239
T146 240-261 TrialDesign denotes randomised controlled
T151 315-325 Type denotes adjunctive
T150 326-333 Therapy denotes therapy
T152 326-333 Therapy denotes therapy
T155 326-333 Therapy denotes therapy
122 339-357 Chemical denotes methylprednisolone drug MESH:D008775
123 362-384 Chemical denotes unfractionated heparin drug MESH:D006493
124 386-389 Chemical denotes UFH drug MESH:D006493
125 399-417 Chemical denotes methylprednisolone drug MESH:D008775
126 422-450 Chemical denotes low molecular weight heparin drug MESH:D006495
127 452-456 Chemical denotes LMWH drug MESH:D006495
T154 462-466 PositiveRegulation denotes more
T153 480-488 NegativeRegulation denotes reducing
128 499-508 Die denotes mortality MESH:D009026
T65 512-526 Severity denotes critically-ill
T149 527-537 Status_of_Care denotes ventilated
130 538-546 Species denotes patients Tax:9606
131 552-561 Disease denotes pneumonia MESH:D011014
132 567-577 Disease denotes SARS-CoV-2 MESH:D000086382
T148 578-587 Disease denotes infection MESH:MESH:D007239
133 600-604 Chemical denotes LMWH drug MESH:D006495
T156 654-666 TrialDesign denotes multi-centre
T157 668-682 TrialDesign denotes interventional
T158 684-698 TrialDesign denotes parallel group
T159 700-711 TrialDesign denotes superiority
T160 713-723 TrialDesign denotes randomized
T161 725-747 TrialDesign denotes investigator sponsored
T162 749-759 TrialDesign denotes three arms
134 767-775 Species denotes Patients Tax:9606
T163 847-855 TrialDesign denotes randomly
T165 913-918 Ratio denotes 1:1:1
135 921-933 Species denotes PARTICIPANTS Tax:9606
T69 971-978 Area denotes Italian
T224 1064-1072 Positive denotes Positive
136 1073-1083 Species denotes SARS-CoV-2 Tax:2697049
T166 1099-1114 Method denotes pharyngeal swab
T167 1118-1139 Biological denotes deep airways material
T70 1153-1173 Therapy denotes pressure ventilation inclusion_criteria
T71 1182-1194 Type denotes non-invasive inclusion_criteria
T75 1198-1206 Type denotes invasive inclusion_criteria
T84 1213-1223 Duration denotes > 24 hours inclusion_criteria
T169 1227-1235 Type denotes Invasive inclusion_criteria
T168 1236-1246 Type denotes mechanical inclusion_criteria
T85 1247-1258 Therapy denotes ventilation inclusion_criteria
T86 1264-1274 Duration denotes < 96 hours inclusion_criteria
T89 1278-1293 Index denotes PaO2/FiO2 ratio inclusion_criteria
T87 1294-1313 Value denotes lower than 150 mmHg inclusion_criteria
T68 1317-1324 Index denotes D-dimer inclusion_criteria MESH:C036309
T88 1331-1340 Times denotes > 6 times inclusion_criteria
T170 1341-1382 Value denotes the upper limit of normal reference range inclusion_criteria
137 1386-1404 Gene denotes C-reactive Protein inclusion_criteria Gene:1401
T90 1405-1413 Times denotes > 6-fold inclusion_criteria
T171 1414-1455 Value denotes upper the limit of normal reference range inclusion_criteria
T135 1483-1493 Age denotes < 18 years exclusion_criteria
T92 1506-1515 Therapy denotes treatment exclusion_criteria
T174 1521-1540 Chemical denotes anticoagulant drugs notCovid19|drug
T136 1544-1552 Biological denotes Platelet exclusion_criteria
T172 1553-1558 Number denotes count exclusion_criteria
T137 1559-1572 Value denotes < 100.000/mm3 exclusion_criteria
T226 1576-1583 Chemical denotes History
T227 1576-1583 Disease denotes History
138 1587-1594 Chemical denotes heparin MESH:D006493
T173 1595-1602 Induce denotes induced
T140 1603-1619 Disease denotes thrombocytopenia history|exclusion_criteria MESH:D013921
T96 1623-1630 Disease denotes Allergy exclusion_criteria http://purl.obolibrary.org/obo/HP_0012393
140 1634-1651 Chemical denotes sodium enoxaparin
141 1661-1665 Chemical denotes LMWH drug MESH:D006495
142 1667-1670 Chemical denotes UFH MESH:D006493
143 1674-1692 Chemical denotes methylprednisolone MESH:D008775
T98 1696-1702 Condition denotes Active exclusion_criteria
144 1703-1711 Disease denotes bleeding exclusion_criteria MESH:D006470
T176 1753-1762 PositiveRegulation denotes high risk
145 1766-1774 Disease denotes bleeding exclusion_criteria MESH:D006470
T175 1775-1791 Negative denotes contraindicating
T97 1792-1815 Therapy denotes anticoagulant treatment exclusion_criteria
T177 1834-1846 Period denotes last 1 month
T100 1871-1876 Biological denotes brain
T101 1878-1884 Biological denotes spinal
T102 1888-1898 Biological denotes ophthalmic
T99 1899-1906 Therapy denotes surgery exclusion_criteria
T105 1910-1917 Therapy denotes Chronic exclusion_criteria
T104 1932-1952 Chemical denotes oral corticosteroids drug|exclusion_criteria
T178 1937-1952 Therapy denotes corticosteroids exclusion_criteria
T106 1956-1965 Condition denotes Pregnancy exclusion_criteria
T107 1969-1982 Condition denotes breastfeeding exclusion_criteria
T179 1986-1994 Positive denotes positive
T108 1995-2009 Method denotes pregnancy test exclusion_criteria
146 2031-2036 Species denotes women exclusion_criteria Tax:9606
T109 2058-2072 Method denotes pregnancy test exclusion_criteria
T180 2142-2157 Status_of_Care denotes life-sustaining
T110 2158-2167 Therapy denotes treatment exclusion_criteria
T111 2172-2180 Condition denotes too sick exclusion_criteria
T181 2215-2221 Severity denotes severe
T112 2222-2230 Disease denotes diseases exclusion_criteria
147 2263-2271 Species denotes patients Tax:9606
T182 2426-2436 TrialDesign denotes LMWH group drug MESH:D017984
149 2438-2446 Species denotes patients Tax:9606
T228 2469-2481 Dose denotes administered
150 2482-2492 Chemical denotes enoxaparin drug MESH:D017984
T3 2496-2524 Amount denotes standard prophylactic dosage
T188 2528-2548 TrialDesign denotes LMWH + steroid group drug MESH:D017984|MESH:D008775
153 2550-2558 Species denotes patients Tax:9606
T229 2578-2585 Dose denotes receive
T230 2578-2585 Dose denotes receive
154 2586-2596 Chemical denotes enoxaparin drug MESH:D017984
T4 2600-2628 Amount denotes standard prophylactic dosage
155 2633-2651 Chemical denotes methylprednisolone drug MESH:D008775
T191 2655-2674 TrialDesign denotes UFH + steroid group drug MESH:D006493|MESH:D008775
158 2676-2684 Species denotes patients Tax:9606
T231 2704-2711 Dose denotes receive
T232 2704-2711 Dose denotes receive
159 2712-2715 Chemical denotes UFH drug MESH:D006493
T5 2719-2738 Amount denotes therapeutic dosages
160 2743-2761 Chemical denotes methylprednisolone drug MESH:D008775
161 2763-2766 Chemical denotes UFH drug MESH:D006493
T7 2775-2787 Dose denotes administered
T193 2788-2801 Biological denotes intravenously
T192 2805-2824 TrialDesign denotes UFH + steroid group drug MESH:D006493|MESH:D008775
T6 2828-2845 Index denotes therapeutic doses
T194 2882-2895 Index denotes infusion rate
T8 2899-2912 Amount denotes 18 UI/kg/hour
T196 2922-2930 Change denotes modified
T9 2941-2951 Index denotes aPTT Ratio
T195 2976-2983 Ratio denotes 1.5-2.0
T197 3032-3055 Interval denotes no longer than 12 hours
164 3076-3079 Chemical denotes UFH drug MESH:D006493
T10 3101-3120 Duration denotes up to ICU discharge
T201 3122-3141 Timing denotes After ICU discharge
T198 3142-3163 Therapy denotes anticoagulant therapy
T199 3171-3182 Interrupt denotes interrupted
T200 3186-3194 Change denotes switched
165 3215-3219 Chemical denotes LMWH drug MESH:D006495
166 3297-3307 Chemical denotes Enoxaparin drug MESH:D017984
T233 3316-3328 Dose denotes administered
T234 3316-3328 Dose denotes administered
T183 3337-3347 TrialDesign denotes LMWH group drug MESH:D017984
T189 3352-3372 TrialDesign denotes LMWH + steroid group drug MESH:D017984|MESH:D008775
T204 3376-3402 Amount denotes standard prophylactic dose
T125 3410-3417 Amount denotes 4000 UI
T126 3418-3426 Interval denotes once day
T124 3441-3448 Amount denotes 6000 UI
T127 3449-3457 Interval denotes once day
170 3462-3470 Species denotes patients Tax:9606
T203 3471-3480 Index denotes weighting
T202 3481-3496 Value denotes more than 90 kg
T14 3521-3533 Dose denotes administered
T205 3534-3548 Biological denotes subcutaneously
T15 3549-3559 Interval denotes once a day
T13 3560-3579 Duration denotes up to ICU discharge
171 3713-3731 Chemical denotes Methylprednisolone drug MESH:D008775
T210 3740-3752 Dose denotes administered
T211 3740-3752 Dose denotes administered
T212 3740-3752 Dose denotes administered
T213 3740-3752 Dose denotes administered
T190 3761-3781 TrialDesign denotes LMWH + steroid group drug MESH:D017984|MESH:D008775
T206 3786-3805 TrialDesign denotes UHF + steroid group drug UFH + steroid group MESH:D006493|MESH:D008775 t
T16 3806-3819 Biological denotes intravenously
T17 3828-3841 Timing denotes initial bolus
T209 3845-3854 Amount denotes 0,5 mg/kg
T131 3885-3894 Amount denotes 0,5 mg/kg
T18 3895-3908 Interval denotes 4 times daily
T19 3909-3919 Timing denotes for 7 days
T132 3921-3930 Amount denotes 0,5 mg/kg
T21 3931-3944 Interval denotes 3 times daily
T22 3945-3965 Timing denotes from day 8 to day 10
T133 3967-3976 Amount denotes 0,5 mg/kg
T24 3977-3990 Interval denotes 2 times daily
T25 3991-4008 Timing denotes at days 11 and 12
T134 4013-4022 Amount denotes 0,5 mg/kg
T27 4023-4033 Interval denotes once daily
T28 4034-4051 Timing denotes at days 13 and 14
176 4106-4115 Die denotes mortality MESH:D009026
T113 4158-4169 Therapy denotes Ventilation
T214 4170-4174 Prevent denotes free
178 4239-4246 Species denotes patient Tax:9606
T216 4260-4264 Prevent denotes free
T115 4268-4279 Therapy denotes ventilation
T77 4288-4296 Type denotes invasive
T72 4300-4312 Type denotes non-invasive
T217 4398-4412 Dose denotes administration
T235 4398-4412 Dose denotes administration
T31 4416-4425 Amount denotes high-dose
179 4426-4434 Chemical denotes steroids drug MESH:D013256
T30 4438-4461 Chemical denotes immune-modulatory drugs drug
T73 4491-4503 Type denotes non-invasive
T219 4507-4526 Type denotes invasive mechanical
T116 4516-4526 Type denotes mechanical
T218 4527-4538 Therapy denotes ventilation
T221 4578-4590 Type denotes non-invasive
T74 4591-4602 Therapy denotes ventilation
T220 4616-4624 Type denotes invasive
T82 4625-4636 Therapy denotes ventilation
180 4650-4659 Die denotes mortality MESH:D009026
182 4825-4835 Disease denotes infections MESH:D007239
183 4876-4886 Disease denotes infections MESH:D007239
T34 4890-4897 Species denotes Candida Tax:1535326
T35 4890-4897 Species denotes Candida Tax:5475
T37 4899-4910 Species denotes Aspergillus Tax:5052
184 4912-4922 Species denotes Adenovirus Tax:10508
T38 4924-4954 Species denotes Herpes Virus e Cytomegalovirus
185 4975-4992 Disease denotes organ dysfunction
186 5059-5081 Disease denotes venous thromboembolism MESH:D054556
187 5083-5089 Disease denotes stroke MESH:D020521
188 5093-5114 Disease denotes myocardial infarction MESH:D009203
189 5156-5164 Disease denotes bleeding MESH:D006470
T41 5177-5188 Method denotes transfusion
T43 5192-5217 Amount denotes 2 or more units of packed
T44 5218-5233 Biological denotes red blood cells
T42 5234-5242 Timing denotes in a day
190 5244-5252 Disease denotes bleeding MESH:D020300
T121 5244-5252 Disease denotes bleeding
T236 5244-5252 Disease denotes bleeding
T45 5314-5326 Disease denotes intracranial
T46 5328-5340 Biological denotes intra-spinal
191 5342-5353 Biological denotes intraocular
T122 5380-5383 Biological denotes eye
T123 5393-5411 Disease denotes conjunctival bleed
T222 5415-5418 Negative denotes not
T49 5442-5453 Biological denotes pericardial
T51 5455-5470 Biological denotes intra-articular
T52 5472-5485 Biological denotes intramuscular
194 5491-5511 Disease denotes compartment syndrome MESH:D003161
T120 5516-5531 Biological denotes retroperitoneal
195 5534-5542 Disease denotes bleeding
T55 5561-5582 Therapy denotes surgical intervention
196 5587-5595 Disease denotes bleeding
197 5624-5632 Disease denotes bleeding MESH:D006470
198 5669-5674 Die denotes death MESH:D003643
199 5702-5707 Die denotes death MESH:D003643
200 5746-5764 Disease denotes non-major bleeding
201 5777-5808 Disease denotes acute clinically overt bleeding
202 5871-5904 Disease denotes bleeding compromising hemodynamic
203 5906-5926 Disease denotes spontaneous hematoma HP:0007420
T57 5927-5945 Size denotes larger than 25 cm2
204 5947-5969 Disease denotes intramuscular hematoma HP:0012233
205 6001-6011 Disease denotes haematuria MESH:D006417
T59 6113-6124 Disease denotes haemoptysis hemoptysis synonym MESH:D006469
206 6126-6137 Disease denotes hematemesis MESH:D006396
207 6141-6168 Disease denotes spontaneous rectal bleeding
208 6222-6240 Disease denotes any other bleeding
T60 6251-6286 Disease denotes temporary cessation of a study drug
T237 6306-6325 TrialDesign denotes block randomisation
T245 6344-6364 TrialDesign denotes variable block sizes
T244 6366-6376 TrialDesign denotes block size
T238 6377-6382 Ratio denotes 4-6-8
T239 6410-6416 TrialDesign denotes Centre
T243 6418-6421 Index denotes BMI inclusion_criteria
T246 6423-6426 Value denotes <30
T247 6427-6430 Value denotes ≥30
T240 6436-6439 Age denotes Age inclusion_criteria
T241 6441-6444 Age denotes <75
T242 6445-6448 Age denotes ≥75
T248 6451-6472 TrialDesign denotes Central randomisation
T249 6567-6572 Ratio denotes 1:1:1
209 6704-6716 Species denotes Participants Tax:9606
T258 6738-6745 TrialDesign denotes blinded
T61 6883-6898 TrialDesign denotes UHF and steroid drug UFH and steroid MESH:D006493|MESH:D008775 t
T184 6910-6920 TrialDesign denotes LMWH group drug MESH:D017984
T253 6915-6920 TrialDesign denotes group
213 6959-6964 Die denotes death MESH:D003643
T254 6988-6999 TrialDesign denotes sample size
T257 7032-7035 Number denotes 210 inclusion_criteria
T255 7043-7056 TrialDesign denotes randomization
T256 7057-7062 Ratio denotes 1:1:1
T260 7067-7074 Number denotes seventy inclusion_criteria
214 7075-7083 Species denotes patients Tax:9606
215 7142-7151 Die denotes mortality MESH:D009026
T185 7160-7170 TrialDesign denotes LMWH group drug MESH:D017984
217 7220-7228 Species denotes patients Tax:9606
218 7323-7328 Die denotes death MESH:D003643
T251 7341-7361 TrialDesign denotes LMHW + steroid group drug LMWH + steroid group MESH:D017984|MESH:D008775 t
T186 7366-7376 TrialDesign denotes LMWH group drug MESH:D017984
T207 7383-7402 TrialDesign denotes UHF + steroid group drug UFH + steroid group MESH:D006493|MESH:D008775 t
T187 7407-7417 TrialDesign denotes LMWH group drug MESH:D017984
224 7481-7501 TrialDesign denotes LMHW + steroid group drug LMWH + steroid group MESH:D017984|MESH:D008775 t
T208 7506-7525 TrialDesign denotes UHF + steroid group drug UFH + steroid group MESH:D006493|MESH:D008775 t
T259 7735-7756 TrialDesign denotes 8 participating sites
228 7788-7796 Species denotes patients Tax:9606
229 7822-7830 Species denotes patients Tax:9606
230 7870-7878 Species denotes patients Tax:9606
T141 7908-7911 Number denotes 210 inclusion_criteria
231 7912-7924 Species denotes participants Tax:9606
R1 11 T147 of_a SARS-CoV-2,infection
R10 T151 T152 of_a adjunctive,therapy
R100 T126 T233 of_a once day,administered
R101 T124 T234 of_a 6000 UI,administered
R102 T127 T234 of_a once day,administered
R103 T202 T203 of_a more than 90 kg,weighting
R104 T203 170 of_a weighting,patients
R105 170 T234 of_a patients,administered
R106 T233 T182 of_a administered,LMWH group
R107 T233 T188 of_a administered,LMWH + steroid group
R108 T234 T182 of_a administered,LMWH group
R109 T234 T188 of_a administered,LMWH + steroid group
R11 T151 T155 of_a adjunctive,therapy
R110 T15 T233 of_a once a day,administered
R111 T15 T234 of_a once a day,administered
R112 T13 T233 in up to ICU discharge,administered
R113 T13 T234 in up to ICU discharge,administered
R114 T205 T233 in subcutaneously,administered
R115 T205 T234 in subcutaneously,administered
R116 T209 T210 of_a "0,5 mg/kg",administered
R117 T17 T210 of_a initial bolus,administered
R118 T18 T210 of_a 4 times daily,administered
R119 171 T210 of_a Methylprednisolone,administered
R12 122 T150 using methylprednisolone,therapy
R120 T19 T210 of_a for 7 days,administered
R121 T132 T211 of_a "0,5 mg/kg",administered
R122 T21 T211 of_a 3 times daily,administered
R123 T22 T211 of_a from day 8 to day 10,administered
R124 171 T211 of_a Methylprednisolone,administered
R125 T16 T210 in intravenously,administered
R126 T16 T211 in intravenously,administered
R127 T133 T212 of_a "0,5 mg/kg",administered
R128 T24 T212 of_a 2 times daily,administered
R129 T25 T212 of_a at days 11 and 12,administered
R13 123 T150 using unfractionated heparin,therapy
R130 T134 T213 of_a "0,5 mg/kg",administered
R131 T27 T213 of_a once daily,administered
R132 T28 T213 of_a at days 13 and 14,administered
R133 171 T212 of_a Methylprednisolone,administered
R134 171 T213 of_a Methylprednisolone,administered
R135 T16 T212 in intravenously,administered
R136 T16 T213 in intravenously,administered
R137 T210 T188 of_a administered,LMWH + steroid group
R138 T211 T188 of_a administered,LMWH + steroid group
R139 T212 T188 of_a administered,LMWH + steroid group
R14 124 123 abbreviation UFH,unfractionated heparin
R140 T213 T188 of_a administered,LMWH + steroid group
R141 T210 T191 of_a administered,UFH + steroid group
R142 T211 T191 of_a administered,UFH + steroid group
R143 T212 T191 of_a administered,UFH + steroid group
R144 T213 T191 of_a administered,UFH + steroid group
R145 T115 T77 of_a ventilation,invasive
R146 T115 T72 of_a ventilation,non-invasive
R147 T31 T217 of_a high-dose,administration
R148 T31 T235 of_a high-dose,administration
R149 179 T217 of_a steroids,administration
R15 127 126 abbreviation LMWH,low molecular weight heparin
R150 T30 T235 of_a immune-modulatory drugs,administration
R151 T43 T41 of_a 2 or more units of packed,transfusion
R152 T44 T41 of_a red blood cells,transfusion
R153 T42 T41 of_a in a day,transfusion
R154 190 T45 - bleeding,intracranial
R155 T122 191 of_a eye,intraocular
R156 T46 T121 in intra-spinal,bleeding
R157 191 T121 in intraocular,bleeding
R158 T222 T123 of_a not,conjunctival bleed
R159 T49 T121 in pericardial,bleeding
R16 125 T152 using methylprednisolone,therapy
R160 T51 T121 in intra-articular,bleeding
R161 T120 T121 in retroperitoneal,bleeding
R162 194 T236 with compartment syndrome,bleeding
R163 T52 T236 in intramuscular,bleeding
R164 196 198 cause_of bleeding,death
R165 195 T55 against bleeding,surgical intervention
R166 T57 203 of_a larger than 25 cm2,spontaneous hematoma
R167 T238 T244 of_a 4-6-8,block size
R168 T240 T241 - Age,<75
R169 T240 T242 - Age,≥75
R17 126 T152 using low molecular weight heparin,therapy
R170 T246 T243 of_a <30,BMI
R171 T247 T243 of_a ≥30,BMI
R172 T249 T248 of_a 1:1:1,Central randomisation
R173 T61 T253 - UHF and steroid,group
R174 231 T141 of_a participants,210
R175 T257 T254 of_a 210,sample size
R176 T256 T255 of_a 1:1:1,randomization
R177 214 T260 of_a patients,seventy
R18 133 T155 using LMWH,therapy
R19 T65 131 of_a critically-ill,pneumonia
R2 T147 9 has_a infection,patients
R20 130 T149 has_status patients,ventilated
R21 132 T148 of_a SARS-CoV-2,infection
R22 T148 130 has_a infection,patients
R23 131 130 has_a pneumonia,patients
R24 T150 T154 is_a therapy,more
R25 T152 T154 is_a therapy,more
R26 T155 T154 against therapy,more
R27 130 T153 is_a patients,reducing
R28 T153 128 is_a reducing,mortality
R29 T154 T153 is_a more,reducing
R3 10 9 has_a pneumonia,patients
R30 T73 T116 - non-invasive,mechanical
R31 T219 T218 of_a invasive mechanical,ventilation
R32 T73 T218 of_a non-invasive,ventilation
R33 T221 T74 of_a non-invasive,ventilation
R34 T220 T82 of_a invasive,ventilation
R35 T34 183 cause_of Candida,infections
R36 T35 183 cause_of Candida,infections
R37 T37 183 cause_of Aspergillus,infections
R38 184 183 cause_of Adenovirus,infections
R39 T38 183 cause_of Herpes Virus e Cytomegalovirus,infections
R4 9 T145 has_status patients,ventilated
R40 T70 T71 of_a pressure ventilation,non-invasive
R41 T70 T75 of_a pressure ventilation,invasive
R42 T84 T70 in > 24 hours,pressure ventilation
R43 T85 T169 of_a ventilation,Invasive
R44 T85 T168 of_a ventilation,mechanical
R45 T86 T85 in < 96 hours,ventilation
R46 T87 T89 of_a lower than 150 mmHg,PaO2/FiO2 ratio
R47 T88 T68 of_a > 6 times,D-dimer
R48 T170 T88 of_a the upper limit of normal reference range,> 6 times
R49 T171 T90 of_a upper the limit of normal reference range,> 6-fold
R5 T64 10 of_a critically ill,pneumonia
R50 T90 137 of_a > 6-fold,C-reactive Protein
R51 T166 T224 using pharyngeal swab,Positive
R52 T167 T166 of_a deep airways material,pharyngeal swab
R53 T224 136 is_a Positive,SARS-CoV-2
R54 T137 T172 of_a < 100.000/mm3,count
R55 T174 T92 using anticoagulant drugs,treatment
R56 T136 T172 of_a Platelet,count
R57 140 T96 against sodium enoxaparin,Allergy
R58 141 T96 against LMWH,Allergy
R59 142 T96 against UFH,Allergy
R6 6 T223 using methylprednisolone,use
R60 143 T96 against methylprednisolone,Allergy
R61 138 T173 is_a heparin,induced
R62 T173 T140 is_a induced,thrombocytopenia
R63 T100 T99 of_a brain,surgery
R64 T101 T99 of_a spinal,surgery
R65 T102 T99 of_a ophthalmic,surgery
R66 T177 T99 in last 1 month,surgery
R67 T176 145 is_a high risk,bleeding
R68 144 T98 has_status bleeding,Active
R69 T175 T97 is_a contraindicating,anticoagulant treatment
R7 7 T223 using unfractionated heparin,use
R70 T97 145 for anticoagulant treatment,bleeding
R71 T105 T178 - Chronic,corticosteroids
R72 T108 T179 using pregnancy test,positive
R73 T110 T180 has_status treatment,life-sustaining
R74 146 T109 for women,pregnancy test
R75 T181 T112 of_a severe,diseases
R76 T3 T228 of_a standard prophylactic dosage,administered
R77 150 T228 of_a enoxaparin,administered
R78 T228 T182 of_a administered,LMWH group
R79 T4 T229 of_a standard prophylactic dosage,receive
R8 T223 9 for use,patients
R80 154 T229 of_a enoxaparin,receive
R81 155 T230 of_a methylprednisolone,receive
R82 T229 T188 of_a receive,LMWH + steroid group
R83 T230 T188 of_a receive,LMWH + steroid group
R84 159 T231 of_a UFH,receive
R85 T5 T231 of_a therapeutic dosages,receive
R86 T193 T231 in intravenously,receive
R87 160 T232 of_a methylprednisolone,receive
R88 T232 T191 of_a receive,UFH + steroid group
R89 T231 T191 of_a receive,UFH + steroid group
R9 T151 T150 of_a adjunctive,therapy
R90 T195 T9 of_a 1.5-2.0,aPTT Ratio
R91 T8 T194 of_a 18 UI/kg/hour,infusion rate
R92 T194 T231 of_a infusion rate,receive
R93 T231 T196 is_a receive,modified
R94 T196 T9 is_a modified,aPTT Ratio
R95 T197 T196 in no longer than 12 hours,modified
R96 T10 T231 in up to ICU discharge,receive
R97 166 T233 of_a Enoxaparin,administered
R98 166 T234 of_a Enoxaparin,administered
R99 T125 T233 of_a 4000 UI,administered